Haleon PLC

Board/Management Information • Oct 2, 2025

National Storage Mechanism | Additional information

RNS Number : 8217B

Haleon PLC

02 October 2025

Haleon plc: Director Declaration

02 October 2025: In accordance with paragraph 6.4.9R(2) of the UK Listing Rules, Haleon plc (LSE/NYSE: HLN) announces that Tracy Clarke, Non-Executive Director, will be appointed to the Board of Inchcape plc (LSE: INCH) as a Non-Executive Director effective 31 December 2025.

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit   www.haleon.com . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNMTBPTMTJMMIA